Robert Fallis, MD
Psychiatry · Nashville, TNNPI 1508867789
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,012 of the $2,012 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, F. Hoffmann-la Roche AG.
Across 5 payments — averaging $402.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$2K
Across 18 payments — averaging $13,381 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$194K
- Biogen$14K
- Alkermes, Inc.$14K
- F. Hoffmann-la Roche AG$12K
- Novartis$6K
What the payments were for
- Speaking & faculty fees$2,012100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 5 | $2,012 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$2,012
How this compares
$2,012 in reported general payments places this provider in the 75th percentile of 503 psychiatry providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 55 | $57,880 |
| UbrelvyUbrogepant | 27 | $27,437 |
| Emgality PenGalcanezumab-Gnlm | 33 | $22,246 |
| Aimovig AutoinjectorErenumab-Aooe | 22 | $17,391 |
| Sumatriptan Succinate | 46 | $14,758 |
| QuliptaAtogepant | 12 | $12,292 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 15 | $10,440 |
| Lacosamide | 38 | $7,600 |
| Dalfampridine ErDalfampridine | 12 | $7,200 |
| Tizanidine Hcl | 651 | $6,423 |
| Solifenacin Succinate | 18 | $4,008 |
| Oxcarbazepine | 52 | $2,313 |
| RizatriptanRizatriptan Benzoate | 111 | $2,090 |
| Levetiracetam | 62 | $2,020 |
| Cyclobenzaprine Hcl | 141 | $1,880 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Nashville
- Rakesh AminNashville$3M
- Robert JamiesonNashville$141K
- Michelle CochranNashville$74K
- Amanda Sparks-BushnellNashville$66K
- Craig ClarkNashville$31K
- Joseph SharpeNashville$29K
- Colleen FriddellNashville$23K
- Jane WeinbergNashville$22K
- Esiri EsinNashville$18K
- Tianlai TangNashville$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.